244 related articles for article (PubMed ID: 15377314)
1. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A in prophylactic treatment of migraine.
Anand KS; Prasad A; Singh MM; Sharma S; Bala K
Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
Petri S; Tölle T; Straube A; Pfaffenrath V; Stefenelli U; Ceballos-Baumann A;
Eur Neurol; 2009; 62(4):204-11. PubMed ID: 19622887
[TBL] [Abstract][Full Text] [Related]
11. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT
Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Blumenfeld AM; Schim JD; Chippendale TJ
Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
Schulte-Mattler WJ; Krack P;
Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
16. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
Brandes JL; Visser WH; Farmer MV; Schuhl AL; Malbecq W; Vrijens F; Lines CR; Reines SA;
Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
19. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
Sahai A; Khan MS; Dasgupta P
J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
